Industry: Pharmaceuticals, Biotechnology
Peplin is focused on the discovery, development and commercialisation of prescription pharmaceuticals for the treatment of cancer. Peplin’s strategy is to leverage its pipeline of novel proprietary products through collaborative development and commercialisation arrangements with international pharmaceutical companies. Peplin’s lead product is a clinical stage topical therapy for actinic keratosis and non-melanoma skin cancer. It is the subject of a US$23 million development collaboration and license agreement with Allergan, Inc. of Irvine, California for commercialisation in North and South America. Peplin retains rest of world rights for PEP005 Topical and all rights world wide to other cancer applications of ( www.peplin.com )
Peplin Limited
P.O. Box 346
Fortitude Valley, Queensland 4006
Australia
Tel: +61 7 3250 1200